Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli or Klebsiella pneumoniae

(2011) Nan-Yao Lee et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem

(2011) K. J. Eagye et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Absence of Association between Use of Ertapenem and Change in Antipseudomonal Carbapenem Susceptibility Rates in 25 Hospitals

(2010) Kathryn J. Eagye et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Pharmacokinetics of Ertapenem following Intravenous and Subcutaneous Infusions in Patients

(2009) D. Frasca et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosa

(2009) E. J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Impact of Ertapenem Use on the Susceptibility of Pseudomonas aeruginosa to Imipenem A Hospital Case Study

(2009) Ana Lucia L. Lima et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Ertapenem: No effect on aerobic gram-negative susceptibilities to imipenem

(2008) Debra A. Goff et al.   JOURNAL OF INFECTION